Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

Erin Davis/Axios VisualsMore than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given ...